3种量表预测急性髓系白血病患者有症状性PICC相关血栓形成风险效果的比较

doi:10.16460/j.issn1008-9969.2023.11.059

摘要/Abstract

摘要： 目的比较Padua量表、Autar量表与 Caprini量表在预测急性髓系白血病患有症状性PICC相关血栓风险的预测效能。方法采用便利抽样法,选取2019年3月—2021年3月在广州市南方医科大学南方医院血液科留置PICC的265例急性髓系白血病患者作为研究对象,采用一般资料调查表、Padua量表、Caprini量表、Autar量表和PICC导管维护随访表收集资料,计算3种评估量表的接受者操作特征曲线下面积并进行两两比较,计算量表的最佳临界值、灵敏度、特异度和约登指数。结果 265例急性髓系白血病患者中,37例患者发生有症状性PICC相关血栓,发生率约14.0%;血栓发生时间为置管后第19.00（9.00,61.00）天。Padua量表、Caprini量表和Autar量表预测该类患者有症状性PICC相关血栓风险时ROC曲线下面积分别是0.784,0.633和0.648,且Padua量表ROC曲线下面积显著高于另外2种量表（P<0.05）。Padua量表的最佳临界值为4分,灵敏度为0.757,特异度为0.680,约登指数为0.437;Caprini量表最佳临界值为8分,灵敏度为0.676,特异度为0.548,约登指数为0.224;Autar量表最佳临界值为10分,灵敏度为0.595,特异度为0.693,约登指数为0.288。结论相较于Caprini量表和Autar量表,Padua量表能够更好地预测急性髓系白血病患者有症状性PICC相关血栓风险,但未来仍需针对具体疾病人群制定特异性的导管相关血栓风险评估工具以提高预测的准确性。

关键词: 急性髓系白血病, 有症状性PICC相关血栓, Padua量表, Caprini量表, Autar量表

Abstract: Objective To compare the predictive power of the Padua, Caprini and Autar scale for venous thromboembolism associated with symptomatic peripherally inserted central catheter (PICC) in patients with acute myeloid leukemia. Methods From March 2019 to March 2021, 265 patients with acute myeloid leukemia with PICC at the Hematology Department of Nanfang Hospital of Southern Medical University were selected using convenient sampling. The General Information Questionnaire, the Padua scale, the Caprini scale, the Autar scale, and the PICC Maintenance Follow-up Tables were used to collect data. The area under the receiver operating characteristic curve (ROC) of the three scales was calculated and pairwise comparison was performed. The best cut-off value, sensitivities, specificity, and Youden exponents of the scales were calculated. Results Of the 265 patients with acute myeloid leukemia, 37 had symptomatic PICC-associated thrombosis, with an incidence of approximate 14.0%;the median interval between PICC insertion and thrombotic episode was the 19.00th (9.00,61.00) day. The area under the ROC curve of Padua scale, Caprini scale and Autar scale was 0.784, 0.633 and 0.648, respectively, and the area under the ROC curve of Padua scale was significantly higher than that of the other two scales (P<0.05). The sensitivity, specificity, and Youden index of the Padua scale were 0.757, 0.680, and 0.437, respectively, with an optimal cutoff of 4. The sensitivity, specificity, and Youden index of the Caprini scale were 0.676, 0.548, and 0.224, respectively, with an optimal cutoff of 8. The sensitivity, specificity, and Youden index of the Autar scale were 0.595, 0.693, and 0.288, respectively, with an optimal cutoff of 10. Conclusion Compared to the Caprini and Autar scale, the Padua scale provides better prediction for the risk of symptomatic PICC-associated thrombosis in patients with acute myeloid leukemia. However, it is still necessary to develop specific catheter-associated thrombosis risk assessment tools for specific disease groups in the future to improve prediction accuracy.

Key words: acute myeloid leukemia, symptomatic PICC-related venous thromboembolism, Padua scale, Caprini scale, Autar scale

中图分类号:

R473.55

许汇娟, 刘颖, 姚嘉丽, 姚晶晶, 陈敏, 邱甜甜, 徐丹. 3种量表预测急性髓系白血病患者有症状性PICC相关血栓形成风险效果的比较[J]. 护理学报, 2023, 30(11): 59-64.

XU Hui-juan, LIU Ying, YAO Jia-li, YAO Jing-jing, CHEN Min, QIU Tian-tian, XU Dan. Predictive power comparison of three different risk assessment models for symptomatic peripherally inserted central catheter related venous thromboembolism among patients with acute myeloblastic leukemia[J]. Journal of Nursing, 2023, 30(11): 59-64.

参考文献

[1] Ren Y, Chang L, Zhao B, et al.Venous Thromboembolism after peripherally inserted central catheters placement in children with acute leukemia: a single-center retrospective cohort study[J]. J Pediatr Hematol Oncol,2020, 42(6):e407-e409. DOI: 10.1097/MPH.0000000000001832.
[2] Lee YG, Kim I, Kwon JH, et al.Implications of cytogenetics for venous thromboembolism in acute myeloid leukaemia[J]. Thromb Haemost, 2015,113(1):201-208.DOI:10.1160/TH13-12-1020.
[3] 国际血管联盟中国分会,中国老年医学学会周围血管疾病管理分会.输液导管相关静脉血栓形成防治中国专家共识(2020版)[J].中国实用外科杂志, 2020, 40(4):377-383.DOI:10.19538/j.cjps.issn1005-2208.2020.04.03.
[4] Gorski LA, Hadaway L, Hagle ME, et al.Infusion therapy standards of practice[J]. [J] Infus Nurs. 2021, 44(s1):S1-S224. DOI:10.1097/NAN.0000000000000396.
[5] Sriskandarajah P, Webb K, Chisholm D, et al.Retrospective cohort analysis comparing the incidence of deep vein thromboses between peripherally-inserted and long-term skin tunneled venous catheters in hemato-oncology patients[J]. Thromb J,2015,25:13-21.DOI:10.1186/s12959-015-0052-2.
[6] Ban T, Fujiwara S I, Rui M, et al.Risk factors for complications associated with peripherally inserted central catheters during induction chemotherapy for acute myeloid leukemia[J]. Intern Med,2022,61(7):989-995.DOI:10.2169/internalmedicine.8184-21.
[7] Bruzzese A, Chistolini A, Morano SG, et al.Peripherally inserted central catheter in patients with acute myeloid leukemia: incidence and risk factors for premature removal[J]. Leuk Lymphoma,2020,61(9):2265-2267. DOI: 10.1080/10428194.2020.1762880.
[8] Del Principe MI, Buccisano F, Maurillo L, et al.Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia[J]. Thromb Res, 2013,132(5):511-514. DOI: 10.1016/j.thromres.2013.08.007.
[9] Lim MY, Al-Kali A, Ashrani AA, et al.Comparison of complication rates of hickman( ) catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapy[J].Leuk Lymphoma,2013, 54(6):1263-1267.DOI:10.3109/10428194.2012.742520.
[10] McKeown C, Ricciuti A, Agha M, et al. A Prospective study of the use of central venous catheters in patients newly diagnosed with acute myeloid leukemia treated with induction chemotherapy[J].Support Care Cancer, 2022,30(2):1673-1679.DOI: 10.1007/s00520-021-06339-x.
[11] Picardi M, Della Pepa R, Cerchione C, et al.A frontline approach with peripherally inserted versus centrally inserted central venous catheters for remission induction chemotherapy phase of acute myeloid leukemia: a randomized comparison[J]. Clin Lymphoma Myeloma Leuk,2019, 19(4):e184-e194. DOI: 10.1016/j.clml.2018.12.008.
[12] 李钱玲,唐玮,李冬雪,等. Caprini风险评估模型评估肿瘤患者PICC相关静脉血栓的有效性研究[J].重庆医科大学学报,2019, 44(7):959-964.DOI:10.13406/j.cnki.cyxb.002199.
[13] Feng Y, Zheng R, Fu Y, et al.Assessing the thrombosis risk of peripherally inserted central catheters in cancer patients using caprini risk assessment model: a prospective cohort study[J]. Support Care Cancer, 2021, 29(9):5047-5055. DOI: 10.1007/s00520-021-06073-4.
[14] 李钱玲,甘秀妮,李源,等. Autar量表与Caprini评估模型对肿瘤患者PICC相关静脉血栓形成预测效果的对比研究[J].护理学报, 2019,26(22):1-5.DOI:10.16460/j.issn1008-9969.2019.22.001.
[15] 朱薇,应燕萍,黄惠桥,等. 三种评分表预测PICC相关上肢深静脉血栓效果比较研究[J]. 护理学杂志, 2018,33(7):54-56. DOI:10.3870/j.issn.1001-4152.2018.07.054.
[16] 万光明. Autar量表在肺癌患者经外周静脉置入中心静脉导管相关上肢静脉血栓形成风险评估中的应用[J]. 中华临床营养杂志,2016,24(6):376-379. DOI:10.3760/cma.j.issn.1674-635X.2016.06.010.
[17] 张亚,岳静,米爱,等. 血液肿瘤患者经外周静脉置入中心静脉导管相关性血栓的临床研究[J]. 四川医学,2022,43(6):593-597. DOI:10.16252/j.cnki.issn1004-0501-2022.06.014.
[18] O'Donnell MR, Tallman MS, Abboud CN, et al. Acute myeloid leukemia, version 3.2017, nccn clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017,15(7):926-957. DOI:10.6004/jnccn.2017.0116.
[19] 李峥,刘宇. 护理学研究方法[M]. 北京:人民卫生出版社,2012.
[20] Caprini JA, Arcelus JI, Hasty JH, et al.Clinical assessment of venous thromboembolic risk in surgical patients[J]. Semin Thromb Hemost, 1991, 17(Suppl 3):304-312.
[21] Caprini JA.Thrombosis risk assessment as a guide to quality patient care[J]. Dis Mon, 2005, 51(2-3):70-78. DOI: 10.1016/j.disamonth.2005.02.003.
[22] Bahl V, Hu HM, Henke PK, et al.A Validation study of a retrospective venous thromboembolism risk scoring method[J]. Ann Surg, 2010, 251(2):344-350. DOI: 10.1097/SLA.0b013e3181b7fca6.
[23] 刘芯言,云洁,吴琪,等. Caprini血栓风险评估表对肿瘤病人静脉血栓栓塞症诊断价值的Meta分析[J]. 护理研究,2022,36(10):1764-1770. DOI:10.12102/j.issn.1009-6493.2022.10.012.
[24] Barbar S, Noventa F, Rossetto V, et al.A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score[J]. J Thromb Haemost, 2010, 8(11):2450-2457. DOI: 10.1111/j.1538-7836.2010.04044.x.
[25] Kahn SR, Lim W, Dunn AS, et al.Prevention of VTE in nonsurgical patients: anti-thrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines[J]. Chest, 2012, 141(2):e195S-e226s. DOI:10.1378/CHEST.11-2296.
[26] 《中国血栓性疾病防治指南》专家委员会. 中国血栓性疾病防治指南[J]. 中华医学杂志, 2018, 98(36):2861-2888. DOI:10.3760/cma.j.issn.0376-2491.2018.36.002.
[27] Autar R.Nursing assessment of clients at risk of deep vein thrombosis (DVT): the Autar DVT Scale[J]. J Adv Nur, 1996,23(4):763-770.DOI:10.1111/j.1365-2648.1996.tb00049.x
[28] Jones D, Wismayer K, Bozas G, et al.The risk of venous thromboembolism associated with peripherally inserted central catheters in ambulant cancer patients[J]. Thromb J, 2017, 15(1):25. DOI:10.1186/s12959-017-0148-y.
[29] 李乾, 赵欣, 张晓维, 等. 国内成人肿瘤患者PICC相关性血栓发生率的Meta分析[J]. 中华护理杂志, 2022, 57(3): 348-355. DOI:10.3761/j.issn.0254-1769.2022.03.016.
[30] Bhargava M, Broccard S, Bai Y, et al.Risk factors for peripherally inserted central catheter line related deep venous thrombosis in critically ill intensive care unit patients[J]. SAGE Open Medicine, 2020, 8:205031212092923. DOI: 10.1177/2050312120929238.
[31] Schiffer CA.Hyperleukocytosis and Leukostasis in Hematologic Malignancies[EB/OL].[2022-06-09].https://www.uptodate.cn/contents/zh-Hans/hyperleukocytosis-and-leukostasis-in-hematologic-malignancies.
[32] Del Principe MI, Del Principe D, Venditti A.Thrombosis in adult patients with acute leukemia[J]. Curr Opin Oncol, 2017,29(6):448-454.DOI:10.1097/CCO.0000000000000402.
[33] Morano SG, Latagliata R, Girmenia C, et al.Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC)[J]. Support Care Cancer, 2015, 23(11):3289-3295. DOI: 10.1007/s00520-015-2740-7.
[34] 陈卫中,倪宗瓒,潘晓平,等. 用ROC曲线确定最佳临界点和可疑值范围[J]. 现代预防医学, 2005,32(7):729-731. DOI:10.3969/j.issn.1003-8507.2005.07.010.
[35] Lin Y, Zeng Z, Lin R, et al.The caprini thrombosis risk model predicts the risk of peripherally inserted central catheter-related upper extremity venous thrombosis in patients with cancer[J]. J Vasc Surg Venous Lymphat Disord, 2021, 9(5):1151-1158. DOI: 10.1016/j.jvsv.2020.12.075.
[36] 马平,宋华. 血液肿瘤患者PICC导管相关性血栓发生原因与预防研究进展[J]. 中国护理管理,2019,19(2):301-305. DOI:10.3969/j.issn.1672-1756.2019.02.029.

Metrics

Viewed

Full text

Abstract

Cited

Shared